Mylan (MYL) Comments on Unfavorable Copaxone Ruling; Reaffirms Expectations for No EPS Impact
Tweet
Share
E-mailGet Alerts MYL Hot Sheet
Join SI Premium – FREE
Mylan Inc. (Nasdaq: MYL) has commented on an unfavorable ruling issued by the U.S. District Court for the Southern District of New York in relation to Teva's patent infringement lawsuit against Mylan in relation to Mylan's proposed generic version of Copaxone.
Mylan CEO Heather Bresch commented: "Although Mylan is disappointed in the Court's decision, and while we have not yet had the opportunity to review the Court's opinion, we fully intend to evaluate our options for an appeal once the Court's full opinion becomes available.
"Importantly and as previously stated, Mylan's earnings guidance for 2012 and earnings targets for 2013 are not reliant on the launch of a generic Copaxone, and therefore our expectations for these periods are unchanged."
Mylan CEO Heather Bresch commented: "Although Mylan is disappointed in the Court's decision, and while we have not yet had the opportunity to review the Court's opinion, we fully intend to evaluate our options for an appeal once the Court's full opinion becomes available.
"Importantly and as previously stated, Mylan's earnings guidance for 2012 and earnings targets for 2013 are not reliant on the launch of a generic Copaxone, and therefore our expectations for these periods are unchanged."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Utah Medical Products (UTMD) Reports Q1 EPS of $1.10
- ResMed (RMD) Tops Q3 EPS by 20c
Create E-mail Alert Related Categories
Corporate News, FDARelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
